title: Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing.
abstract: Inhibitors of proteolytic enzymes (proteases) are emerging as prospective treatments for diseases such as AIDS and viral infections, cancers, inflammatory disorders, and Alzheimer's disease. Generic approaches to the design of protease inhibitors are limited by the unpredictability of interactions between, and structural changes to, inhibitor and protease during binding. A computer analysis of superimposed crystal structures for 266 small molecule inhibitors bound to 48 proteases (16 aspartic, 17 serine, 8 cysteine, and 7 metallo) provides the first conclusive proof that inhibitors, including substrate analogues, commonly bind in an extended beta-strand conformation at the active sites of all these proteases. Representative superimposed structures are shown for (a) multiple inhibitors bound to a protease of each class, (b) single inhibitors each bound to multiple proteases, and (c) conformationally constrained inhibitors bound to proteases. Thus inhibitor/substrate conformation, rather than sequence/composition alone, influences protease recognition, and this has profound implications for inhibitor design. This conclusion is supported by NMR, CD, and binding studies for HIV-1 protease inhibitors/substrates which, when preorganized in an extended conformation, have significantly higher protease affinity. Recognition is dependent upon conformational equilibria since helical and turn peptide conformations are not processed by proteases. Conformational selection explains the resistance of folded/structured regions of proteins to proteolytic degradation, the susceptibility of denatured proteins to processing, and the higher affinity of conformationally constrained 'extended' inhibitors/substrates for proteases. Other approaches to extended inhibitor conformations should similarly lead to high-affinity binding to a protease.
authors.affiliation: Centre for Drug Design and Development, University of Queensland, Brisbane, Queensland 4072, Australia. d.fairlie@mailbox.uq.edu.au
authors.forename: D P
authors.initials: DP
authors.lastname: Fairlie
authors.forename: J D
authors.initials: JD
authors.lastname: Tyndall
authors.forename: R C
authors.initials: RC
authors.lastname: Reid
authors.forename: A K
authors.initials: AK
authors.lastname: Wong
authors.forename: G
authors.initials: G
authors.lastname: Abbenante
authors.forename: M J
authors.initials: MJ
authors.lastname: Scanlon
authors.forename: D R
authors.initials: DR
authors.lastname: March
authors.forename: D A
authors.initials: DA
authors.lastname: Bergman
authors.forename: C L
authors.initials: CL
authors.lastname: Chai
authors.forename: B A
authors.initials: BA
authors.lastname: Burkett
mesh_terms: D000595:Amino Acid Sequence; D001665:Binding Sites; D002851:Chromatography, High Pressure Liquid; D002942:Circular Dichroism; D018360:Crystallography, X-Ray; D015195:Drug Design; D010450:Endopeptidases / Q000737:chemistry* / Q000378:metabolism; D016333:HIV Protease / Q000737:chemistry; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D008969:Molecular Sequence Data; D015394:Molecular Structure; D011480:Protease Inhibitors / Q000737:chemistry*; D011485:Protein Binding; D017433:Protein Structure, Secondary; D013379:Substrate Specificity
chemical_list: D011480:Protease Inhibitors; D010450:Endopeptidases; D016333:HIV Protease